Therapeutic cancer vaccines have become increasingly qualified for use in personalized
cancer immunotherapy. A deeper understanding of tumor immunology and novel antigen …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …

Therapeutic cancer vaccines have gained significant popularity in recent years as new
approaches for specific oncologic indications emerge. Three therapeutic cancer vaccines …

This comprehensive review delves into the rapidly evolving arena of cancer vaccines.
Initially, we examine the intricate constitution of the tumor microenvironment (TME), a …

With the spotlight on cancer immunotherapy and the expanding use of immune checkpoint
inhibitors, strategies to improve the response rate and duration of current cancer …

There are strong biologic and preclinical rationales for the development of therapeutic
cancer vaccines; however, the clinical translation of this treatment strategy has been …

Due to the intrinsic genetic instability of tumor cells, aberrant and novel tumor antigens can
be expressed and serve as potential targets for cancer immunotherapy. This intrinsic feature …

Cancer immunotherapy can induce sustained responses in patients with cancers in a broad
range of tissues, however, these treatments require the optimized combined therapeutic …

After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …